Abstract
973P Atezolizumab plus bevacizumab or lenvatinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: Overall survival using real-world data from TrinetX platform
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have